Stifel Nicolaus Begins Coverage on Inventiva (NASDAQ:IVA)

Stock analysts at Stifel Nicolaus began coverage on shares of Inventiva (NASDAQ:IVA – Get Rating) in a research note issued to investors on Thursday, The Fly reports. The brokerage set a “buy” rating on the stock.

Inventiva Stock Down 6.3 %

NASDAQ:IVA traded down $0.29 during mid-day trading on Thursday, hitting $4.27. 14,937 shares of the company’s stock traded hands, compared to its average volume of 7,487. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.14 and a current ratio of 4.16. The firm’s 50 day simple moving average is $5.64 and its 200 day simple moving average is $4.91. Inventiva has a 1 year low of $3.49 and a 1 year high of $12.15.

Hedge Funds Weigh In On Inventiva

Several hedge funds have recently added to or reduced their stakes in IVA. OLD Mission Capital LLC purchased a new stake in shares of Inventiva during the fourth quarter worth about $25,000. Morgan Stanley grew its holdings in shares of Inventiva by 300.0% during the fourth quarter. Morgan Stanley now owns 6,000 shares of the company’s stock worth $27,000 after buying an additional 4,500 shares in the last quarter. Finally, Yiheng Capital Management L.P. grew its holdings in shares of Inventiva by 59.3% during the second quarter. Yiheng Capital Management L.P. now owns 2,640,253 shares of the company’s stock worth $14,970,000 after buying an additional 982,679 shares in the last quarter. 21.86% of the stock is currently owned by hedge funds and other institutional investors.

About Inventiva

(Get Rating)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.